Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
A Case Report of Prostate Cancer With Leptomeningeal Metastasis and Bone Marrow Involvement Publisher



Garousi M1 ; Mousavi Darzikolaee N2, 3 ; Faridfar A4 ; Javadi SM5 ; Samizadeh E6 ; Sajadi Rad M1 ; Bayani R2, 3
Authors
Show Affiliations
Authors Affiliations
  1. 1. Department of Radiation Oncology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran
  2. 2. Radiation Oncology Research Center, Cancer Institute, Tehran University of Medical Sciences, Tehran, Iran
  3. 3. Department of Radiation Oncology, Imam Khomeini Hospital Complex, School of medicine, Tehran University of Medical Sciences, Tehran, Iran
  4. 4. Research Center for Cancer Screening and Epidemiology, AJA University of Medical Sciences, Tehran, Iran
  5. 5. General Surgery Department, Hamadan University of Medical Sciences, Hamadan, Iran
  6. 6. Department of pathology, School of medicine AND Imam Reza Hospital, AJA University of Medical Sciences, Tehran, Iran

Source: Cancer Reports Published:2024


Abstract

Background: Prostate cancer is the second most common cancer in men. Central nervous system (CNS) involvement in prostate cancer which manifests as cerebral, leptomeningeal, or dural involvement is uncommon and occurs late in the course of disease. Case: A 60-year-old patient with castration resistant prostate cancer (CRPC) presented with headache and fatigue. Evaluation revealed bone marrow and leptomeningeal involvement. The patient treated by whole brain radiotherapy, leuprolide, weekly docetaxel and daily 1000 mg abiraterone. Complete blood count (CBC) and CNS symptoms improved and the patient is alive after 11 months with excellent performance status. Conclusion: Leptomeningeal involvement in prostate cancer is rare and is associated with a poor prognosis but the possibility of such event should be considered in patients with new onset progressive CNS symptoms. New treatment strategies such as combination of docetaxel and abiraterone added to androgen deprivation therapy (triplet therapy) might improve outcome in these patients. © 2024 The Authors. Cancer Reports published by Wiley Periodicals LLC.